Close mobile menu×
Close mobile menu

Andrew S. Bomback, MD

Board Certifications: 
Nephrology, Internal Medicine
Accepting New Patients
Profile Headshot

Appointments

Phone Appointments

New and Existing Patients: 
(212) 305-0320

myColumbiaDoctors

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

America's Top Doctor

Board Certifications

  • Nephrology
  • Internal Medicine

Education & Training

  • Columbia University College of Physicians and Surgeons
  • Residency: University of North Carolina Hospital
  • Fellowship: University of North Carolina Hospital

About Andrew Bomback

Andrew S. Bomback, MD, MPH is a nephrologist who specializes in glomerular diseases and resistant hypertension. Dr. Bomback received his undergraduate degree from Harvard University and his medical degree from Columbia University College of Physicians and Surgeons. He completed residency in Internal Medicine and fellowships in Nephrology and Clinical Epidemiology at the University of North Carolina at Chapel Hill, where he was the Doc J. Thurston III Fellow in Nephrology and Hypertension. In 2009, he returned to Columbia University as an associate at the Center for Glomerular Diseases. He is currently Assistant Professor of Medicine at Columbia University Medical Center.

Dr. Bomback has published over 100 peer-reviewed articles and book chapters on the subjects of chronic kidney disease, glomerular diseases, and hypertension. He is the co-author of the textbook, Chronic Kidney Disease and Hypertension Essentials. He currently serves on the steering and publications committees for the National Kidney Foundation's Kidney Early Evaluation Program (KEEP). He is the recipient of the 2013 Daniel V. Kimberg Junior Faculty Award for oustanding teaching of medical students and housestaff.

Dr. Bomback's research interests are evaluating novel therapies for glomerular diseases and further delineating the role of aldosterone in chronic kidney disease. He currently serves as principal or co-investigator on clinical trials of new treatments for IgA nephropathy, membranous nephropathy, lupus glomerulonephritis, C3 glomerulopathy, and focal segmental glomerulosclerosis.

Academic Titles

  • Assistant Professor of Medicine at CUMC

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Gender

  • Male

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Indemnity
  • Medicare Managed Care
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Access (Exchange)
  • Essential Plan
  • Medicaid Managed Care
  • Medicare Managed Care

Amida Care

  • Special Needs Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • HMO
  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • Blue Priority
  • EPO
  • HMO
  • Indemnity
  • Medicare (Mediblue)
  • NYP Employee Plan
  • Pathway (Exchange)
  • POS
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Medicare

  • Traditional Medicare (NY)

Multiplan

  • Multiplan

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

POMCO

  • POMCO

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • EPO
  • Essential Plan
  • HMO
  • Indemnity
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • SelectHealth

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
161 Fort Washington Avenue
Room 202
New York, New York 10032
Phone: (212) 305-0320
Fax:
(212) 342-1814
Primary

Research

  • Aliskiren vs. valsartan vs. aliskiren/valsartan therapy of proteinuric kidney disease
  • Acthar (ACTH gel) for refractory nephrotic syndrome
  • Eculizumab for dense deposit disease and C3 glomerulonephritis
  • Rituximab for IgA nephropathy
  • Laquinimod for active lupus nephritis
  • Lupus nephritis biomarker study
  • NEPTUNE (Nephrotic syndrome study network)
  • Novel therapies in resistant FSGS

Research Interests

  • Novel therapies for glomerular diseases
  • Role of aldosterone in chronic kidney disease
  • Obesity/metabolic syndrome

Grants

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CCX168 (AVACOPAN) IN PATIENTS WITH ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA)- ASSOCIATED VASCULITIS TREATED CONCOMITANTLY WITH RITUXIMAB OR (P&S Industry Clinical Trial)

Apr 25 2017 - Apr 25 2022

A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, DOSE ASSESSMENT PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CCX168 IN SUBJECTS WITH ANTI- NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA)- ASSOCIATED VASCULITIS (P&S Industry Clinical Trial)

Nov 26 2014 - Nov 26 2019

ANCESTRY, GENETIC RISK AND HEALTH DISPARITIES IN GLOMERULAR DISEASES (Federal Gov)

Jul 10 2014 - Apr 30 2019

ADVANCING CLINICAL RESEARCH IN PRIMARY GLOMERULAR DISEASES (UM1) (Federal Gov)

Sep 16 2013 - May 31 2018

LUPUS NEPHRITIS BIOMARKER STUDY: BASELINE CHARACTERISTICS OF PATIENTS (Private)

Jan 1 2011 - Dec 31 2013

LUPUS NEPHRITIS BIOMARKER STUDY: BASELINE CHARACTERISTICS OF PATIENTS (Private)

Jan 1 2011 - Dec 31 2012

Selected Publications

  • Bomback AS, Muskala P, Bald E, Chwatko G, Nowicki M (2009) Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage Clin Nephrol 72(6):449-456
  • Bomback AS, Kshirsagar AV, Whaley-Connell AT, Chen SC, Li S, Klemmer PJ, McCullough PA, Bakris GL (2010) Racial differences in kidney function among individuals with obesity and metabolic syndrome: results from the Kidney Early Evaluation Program (KEEP) Am J Kidney Dis 55(3 Suppl 2):S4-S14
  • Bomback AS, Derebail VK, Shoham DA, Anderson CA, Steffen LM, Rosamond WD, Kshirsagar AV (2010) Sugar-sweetened soda consumption, hyperuricemia, and kidney disease Kidney Int 77(7):609-616
  • Bomback AS, Appel GB (2010) Updates on the treatment of lupus nephritis J Am Soc Nephrol 21(12):2028-2035
  • Bomback AS, Rekhtman Y, Whaley-Connell AT, Kshirsagar AV, Sowers JR, Chen SC, Li S, Chinnaiyan KM, Bakris GL, McCullough PA (2010) Gestational diabetes mellitus alone in the absence of subsequent diabetes is associated with microalbuminuria: results from the Kidney Early Evaluation Program (KEEP) Diabetes Care 33(12):2586-2591
  • Bomback AS, Song H, D'Agati VD, Cohen SD, Neal A, Appel GB, Rovin BH (2010) A new apolipoprotein E mutation, apoE Las Vegas, in a European-American with lipoprotein glomerulopathy Nephrol Dial Transplant 25:3442-3446
  • Bomback AS, Appel GB, Radhakrishnan J, Shirazian S, Herlitz LC, Stokes B, D'Agati VD, Markowitz GS (2011) ANCA-associated glomerulonephritis in the very elderly Kidney Int 79(7):757-764
  • Bomback AS, Herlitz LC, Markowitz GS (2012) Renal biopsy in the elderly and very elderly: useful or not? Adv Chronic Kidney Dis 19(2):61-67
  • Bomback AS, Smith RJ, Barile GR, Zhang Y, Heher EC, Herlitz L, Stokes MB, Markowitz GS, D'Agati VD, Canetta PA, Radhakrishnan J, Appel GB (2012) Eculizumab for Dense Deposit Disease and C3 Glomerulonephritis Clin J Am Soc Nephrol 7(5):748-756
  • Bomback AS, Canetta PA, Beck Jr LH, Ayalon R, Radhakrishnan J, Appel GB (2012) Treatment of Resistant Glomerular Diseases with Adrenocorticotropic Hormone Gel: A Prospective Trial Am J Nephrol 36(1):58-67